Drug-discovery firm nets $14.5M in Series A funding - MedCity News

Firm leverages AI technology similar to facial recognition to figure out which small molecules can bind most effectively with targeted enzymes. Does the future of drug development lie in a kind of facial-recognition technology for enzymes? That is the hope of X-37 LLC, a drug-development startup that is using artificial intelligence and a deep neural network developed by San Francisco-based Atomwise. "We think that this is an approach and a technology that is really going to transform drug discovery across the board," said Dr. David Collier, CEO of X-37, which is partly owned by Atomwise and is based in South San Francisco, California. It was founded last year.